



Latest clinical trials in Canada as of February 18, 2016

1	Recruiting	<p><u>Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada</u></p> <p>Condition: Chronic Hepatitis C</p> <p>Intervention:</p> <p>Phase:</p> <p>Number Enrolled: 600</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02581189</p> <p>Other IDs: P15-651</p> <p>Title Acronym: AMBER</p> <p>Study Start: October 2015</p> <p>Primary Completion: March 2018</p> <p>Last Verified: February 2016</p>
2	Recruiting	<p><u>Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)</u></p> <p>Condition: Hepatitis C</p> <p>Interventions: Drug: Grazoprevir; Drug: MK-3682; Drug: Elbasvir; Drug: MK-8408; Drug: MK-3682B; Drug: RBV</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 500</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02332720</p>

		<p>Other IDs: 3682-012, 2014-003347-35</p> <p>Title Acronym:</p> <p>Study Start: January 2015</p> <p>Primary Completion: September 2016</p> <p>Last Verified: February 2016</p>
<p>3</p>	<p>Recruiting</p>	<p><u>Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care</u></p> <p>Conditions: Active or Ex-injection Drug Users; Indication of Hepatitis C Screening</p> <p>Interventions: Device: Oraquick HCV Rapid Antibody Test; Device: Standard algorithm</p> <p>Phase:</p> <p>Number Enrolled: 150</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02084719</p> <p>Other IDs: 01</p> <p>Title Acronym:</p> <p>Study Start: March 2014</p> <p>Primary Completion: September 2016</p> <p>Last Verified: January 2016</p>

4	Recruiting	<p><u>Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection</u></p> <p>Condition: Chronic Hepatitis C</p> <p>Interventions: Drug: Simeprevir; Drug: Sofosbuvir</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 30</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02253550</p> <p>Other IDs: TMC435HPC2012</p> <p>Title Acronym:</p> <p>Study Start: October 2014</p> <p>Primary Completion: January 2016</p> <p>Last Verified: June 2015</p>
5	Recruiting	<p><u>Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial</u></p> <p>Condition: Hepatitis C</p> <p>Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)</p> <p>Phase:</p> <p>Number Enrolled: 1850</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT01492504</p> <p>Other IDs: AI444-046, 2011-005287-21</p> <p>Title Acronym:</p> <p>Study Start: February 2012</p>

		<p>Primary Completion: February 2021</p> <p>Last Verified: February 2016</p>
6	Recruiting	<p><u>A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</u></p> <p>Condition: Chronic Hepatitis C Virus (HCV) Infection Genotype 1</p> <p>Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin (RBV)</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 1650</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02219490</p> <p>Other IDs: M14-423, 2014-001022-14</p> <p>Title Acronym: TOPAZ-I</p> <p>Study Start: November 2014</p> <p>Primary Completion: September 2016</p> <p>Last Verified: January 2016</p>
7	Recruiting	<p><u>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection</u></p> <p>Conditions: Chronic Hepatitis C; Hepatitis C Virus</p> <p>Interventions: Drug: ABT-493; Drug: ABT-530; Drug: Ribavirin (RBV); Drug: ABT-493/ABT-530</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 725</p>

		<p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02243293</p> <p>Other IDs: M14-868, 2014-002927-90</p> <p>Title Acronym:</p> <p>Study Start: September 2014</p> <p>Primary Completion: September 2016</p> <p>Last Verified: February 2016</p>
8	Recruiting	<p>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection</p> <p>Conditions: Chronic Hepatitis C; Hepatitis C Virus; HCV</p> <p>Intervention: Drug: ABT-493/ABT-530</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 620</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02604017</p> <p>Other IDs: M13-590, 2015-002087-17</p> <p>Title Acronym:</p> <p>Study Start: January 2015</p> <p>Primary Completion: January 2017</p> <p>Last Verified: January 2016</p>
9	Recruiting	<p>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis</p> <p>Conditions Hepatitis C Virus Infection; Chronic Hepatitis C; Compensated : Cirrhosis</p>

		<p>Intervention: Drug: ABT-493/ABT-530</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 175</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02642432</p> <p>Other IDs: M14-172, 2015-003797-32</p> <p>Title Acronym: EXPEDITION-1</p> <p>Study Start: December 2015</p> <p>Primary Completion: September 2016</p> <p>Last Verified: January 2016</p>
10	Recruiting	<p>A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection</p> <p>Conditions: Chronic Hepatitis C; Hepatitis C Virus; Genotype 3 Hepatitis C Virus</p> <p>Interventions: Drug: ABT-493/ABT-530; Drug: sofosbuvir; Drug: daclatasvir</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 345</p>

		<p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02640157</p> <p>Other IDs: M13-594, 2015-002272-24</p> <p>Title Acronym: ENDURANCE-3</p> <p>Study Start: November 2015</p> <p>Primary Completion: December 2016</p> <p>Last Verified: January 2016</p>
<p>1 1</p>	<p>Recruiting</p>	<p><u>A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults</u></p> <p>Conditions: Hepatitis C Infection; Hepatitis C Virus</p> <p>Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: dasabuvir</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 160</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02582632</p> <p>Other IDs: M15-684, 2015-003370-33</p> <p>Title Acronym:</p> <p>Study Start: November 2015</p> <p>Primary Completion: November 2016</p> <p>Last Verified: January 2016</p>

<p>1 2</p>	<p>Not yet recruiting</p>	<p>A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection</p> <p>Condition: Hepatitis C</p> <p>Interventions: Drug: DCV; Drug: SOF; Drug: RBV</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 75</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02673489</p> <p>Other IDs: AI444-379, 2015-004331-12</p> <p>Title Acronym:</p> <p>Study Start: March 2016</p> <p>Primary Completion: May 2017</p> <p>Last Verified: February 2016</p>
<p>1 3</p>	<p>Recruiting</p>	<p>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection</p> <p>Condition: Chronic Hepatitis C Virus (HCV) Infection</p> <p>Intervention: Drug: ABT-493/ABT-530</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 100</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02651194</p> <p>Other IDs: M15-462</p> <p>Title Acronym: EXPEDITION-4</p> <p>Study Start: December 2015</p> <p>Primary Completion: October 2016</p>

		Last Verified: January 2016
14	Recruiting	<p>The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)</p> <p>Condition: Hepatitis C Virus</p> <p>Intervention: Drug: ABT-493/ABT-530</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 130</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02636595</p> <p>Other IDs: M13-583, 2015-002349-80</p> <p>Title Acronym:</p> <p>Study Start: November 2015</p> <p>Primary Completion: June 2016</p> <p>Last Verified: February 2016</p>
15	Not yet recruiting	<p>Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.</p> <p>Condition: Hepatitis C</p> <p>Interventions: Drug: SOF/VEL for 6 weeks; Drug: SOF/VEL for 12 weeks</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 250</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02625909</p> <p>Other IDs: VHCRP1401</p> <p>Title Acronym: REACT</p>

		<p>Study Start: January 2016</p> <p>Primary Completion: August 2018</p> <p>Last Verified: December 2015</p>
16	Recruiting	<p><u>Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy</u></p> <p>Condition: Hepatitis C</p> <p>Interventions: Drug: SOF/VEL/GS-9857; Drug: SOF/VEL</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 780</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02607800</p> <p>Other IDs: GS-US-367-1172, 2015-003460-36</p> <p>Title Acronym: POLARIS-2</p> <p>Study Start: November 2015</p> <p>Primary Completion: January 2017</p> <p>Last Verified: January 2016</p>
17	Recruiting	<p><u>Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy</u></p> <p>Condition: Hepatitis C</p> <p>Interventions: Drug: SOF/VEL/GS-9857; Drug: Placebo</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 380</p> <p>Age Groups: Adult / Senior</p>

		<p>NCT Number: NCT02607735</p> <p>Other IDs: GS-US-367-1171, 2015-003455-21</p> <p>Title Acronym: POLARIS-1</p> <p>Study Start: November 2015</p> <p>Primary Completion: January 2017</p> <p>Last Verified: January 2016</p>
18	Recruiting	<p><u>Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor</u></p> <p>Condition: Hepatitis C Virus Infection</p> <p>Interventions: Drug: SOF/VEL/GS-9857; Drug: SOF/VEL</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 380</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02639247</p> <p>Other IDs: GS-US-367-1170, 2015-003167-10</p> <p>Title Acronym:</p> <p>Study Start: December 2015</p> <p>Primary Completion: December 2016</p> <p>Last Verified: January 2016</p>
19	Recruiting	<p><u>Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis</u></p> <p>Condition: Hepatitis C Virus Infection</p> <p>Interventions: Drug: SOF/VEL/GS-9857; Drug: SOF/VEL</p> <p>Phase: Phase 3</p>

		<p>Number Enrolled: 200</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02639338</p> <p>Other IDs: GS-US-367-1173, 2015-002996-12</p> <p>Title Acronym:</p> <p>Study Start: December 2015</p> <p>Primary Completion: December 2016</p> <p>Last Verified: January 2016</p>
20	Recruiting	<p>A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects</p> <p>Condition Chronic Hepatitis C Infection</p> <p>:</p> <p>Interventions: Drug: ombitasvir; Drug: paritaprevir; Drug: ritonavir; Drug: dasabuvir; Drug: ribavirin</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 186</p> <p>Age Group: Child</p> <p>NCT Number: NCT02486406</p> <p>Other IDs: M14-748, 2015-000111-41</p> <p>Title Acronym: ZIRCON</p> <p>Study Start: October 2015</p>

		<p>Primary Completion: September 2019</p> <p>Last Verified: January 2016</p>
21	Recruiting	<p>Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</p> <p>Condition: Hepatitis C Virus</p> <p>Interventions: Drug: Simeprevir 150 mg; Drug: Daclatasvir 60 mg; Drug: Sofosbuvir 400 mg</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 90</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02349048</p> <p>Other IDs: CR105963, TMC435HPC2013</p> <p>Title Acronym: ACCORDION-1</p> <p>Study Start: January 2015</p> <p>Primary Completion: February 2016</p> <p>Last Verified: February 2016</p>
22	Recruiting	<p>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</p>

		<p>Condition: Chronic Hepatitis C Virus Infection</p> <p>Interventions: Drug: Ombitasvir/ABT-450/r; Drug: Sofosbuvir; Drug: Ribavirin (RBV)</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 70</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02292719</p> <p>Other IDs: M14-567, 2014-003147-35</p> <p>Title Acronym:</p> <p>Study Start: December 2014</p> <p>Primary Completion: May 2017</p> <p>Last Verified: January 2016</p>
<p>2 3</p>	<p>Recruiting</p>	<p>A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</p> <p>Condition: Hepatitis C, Chronic</p> <p>Interventions: Drug: Simeprevir (SMV); Drug: Ledipasvir (LDV); Drug: Sofosbuvir (SOF)</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 40</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02421211</p> <p>Other IDs: CR106992, TMC435HPC2017, 2015-000459-25</p>

		<p>Title</p> <p>Acronym:</p> <p>Study Start: May 2015</p> <p>Primary Completion: November 2015</p> <p>Last Verified: January 2016</p>
24	Recruiting	<p><u>Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies</u></p> <p>Condition: Hepatitis C Virus Infection</p> <p>Interventions: Drug: LDV/SOF; Drug: RBV</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 300</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02600351</p> <p>Other IDs: GS-US-337-1746</p> <p>Title Acronym:</p> <p>Study Start: November 2015</p> <p>Primary Completion: January 2017</p> <p>Last Verified: January 2016</p>
25	Not yet recruiting	<p><u>Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection</u></p> <p>Conditions: Hepatitis C, Chronic; Cirrhosis, Decompensated</p> <p>Intervention: Drug: Ledipasvir/Sofosbuvir</p>

		<p style="text-align: center;">Phase: Phase 3</p> <p style="text-align: center;">Number Enrolled: 30</p> <p style="text-align: center;">Age Groups: Adult / Senior</p> <p style="text-align: center;">NCT Number: NCT02597166</p> <p style="text-align: center;">Other IDs: IN-CA-337-1960</p> <p style="text-align: center;">Title Acronym:</p> <p style="text-align: center;">Study Start: December 2015</p> <p style="text-align: center;">Primary Completion: December 2017</p> <p style="text-align: center;">Last Verified: November 2015</p>
<p style="text-align: center;">2 6</p>	<p style="text-align: center;">Recruiting</p>	<p><u>A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma</u></p> <p>Condition: Chronic Hepatitis C Infection</p> <p>Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: Dasabuvir; Drug: Ribavirin</p> <p style="text-align: center;">Phase: Phase 3</p> <p>Number Enrolled: 60</p> <p style="text-align: center;">Age Groups: Adult / Senior</p> <p style="text-align: center;">NCT Number: NCT02504099</p> <p>Other IDs: M14-726, 2015-001049-10</p> <p style="text-align: center;">Title Acronym:</p>

		<p>Study Start: July 2015</p> <p>Primary Completion: September 2016</p> <p>Last Verified: February 2016</p>
27	Recruiting	<p>Adult-to-Adult Living Donor Transplant Cohort Study</p> <p>Conditions: Liver Diseases; Hepatocellular Cancer; End Stage Liver Disease; Hepatitis C; Liver Cirrhosis</p> <p>Intervention:</p> <p>Phase:</p> <p>Number Enrolled: 1900</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT01619475</p> <p>Other IDs: A2ALL Core Protocol, 5U01DK062498-09</p> <p>Title Acronym: A2ALL-2</p> <p>Study Start: February 2011</p> <p>Primary Completion: August 2014</p>

		<p>Last Verified: May 2014</p>
28	Recruiting	<p>Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)</p> <p>Condition: Hepatitis C Viral Infection</p> <p>Intervention: Drug: Sofosbuvir (SOF) and Ledipasvir (LDV)</p> <p>Phase: Phase 3</p> <p>Number Enrolled: 20</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02478229</p> <p>Other IDs: 15-8883-A</p> <p>Title Acronym:</p> <p>Study Start: June 2015</p> <p>Primary Completion: June 2016</p> <p>Last Verified: February 2016</p>
29	Recruiting	<p>Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound</p> <p>Conditions: Hepatitis C; Hepatitis B; Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)</p> <p>Intervention: Device: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography</p> <p>Phase:</p> <p>Number Enrolled: 108</p> <p>Age Groups: Adult / Senior</p>

		<p>NCT Number: NCT02044523</p> <p>Other IDs: CE12.062</p> <p>Title Acronym: ELF</p> <p>Study Start: January 2014</p> <p>Primary Completion: July 2018</p> <p>Last Verified: January 2016</p>
<p>30</p>	<p>Not yet recruiting</p>	<p>Improving Outcomes With Metformin</p> <p>Conditions: HIV Infection; Hepatitis C</p> <p>Interventions: Drug: Metformin; Other: No treatment</p> <p>Phase: Phase 2</p> <p>Number Enrolled: 60</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT02306070</p> <p>Other IDs: CTNPT 019</p> <p>Title Acronym:</p> <p>Study Start: January 2016</p> <p>Primary Completion: September 2017</p>

		Last Verified: November 2015
31	Recruiting	<p><u>Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Subjects With Advanced Liver Cancer</u></p> <p>Condition: Hepatocellular Carcinoma</p> <p>Interventions: Biological: Nivolumab; Drug: Sorafenib; Drug: Ipilimumab</p> <p>Phases: Phase 1 / Phase 2</p> <p>Number Enrolled: 600</p> <p>Age Groups: Adult / Senior</p> <p>NCT Number: NCT01658878</p> <p>Other IDs: CA209-040, 2012-001514-42</p> <p>Title</p> <p>Acronym:</p> <p>Study Start: September 2012</p> <p>Primary Completion: December 2016</p> <p>Last Verified: November 2015</p>